Omidria

Drug Overview

In the highly specialized field of Ophthalmology, success in microsurgery depends significantly on the stability and visibility of the internal structures of the eye. Cataract surgery, one of the most common medical procedures performed globally, requires a widely dilated and stable pupil to ensure the safe removal of the cloudy natural lens and the precise placement of an artificial intraocular lens. Omidria is a sophisticated clinical agent designed specifically to optimize these surgical conditions.

Omidria belongs to the Mydriatic / NSAID drug class. It is a unique combination product that provides a Targeted Therapy approach to managing the physiological environment of the eye during the intraoperative period. Unlike standard daily drops, this medication is utilized exclusively in the surgical suite to prevent the complications associated with pupil constriction and post-operative pain.

• Generic Name / Active Ingredient: Phenylephrine and Ketorolac
• US Brand Names: Omidria
• Route of Administration: Intraocular Irrigation (added to the balanced salt solution during surgery)
• FDA Approval Status: Fully FDA-approved for use during cataract surgery or intraocular lens replacement.

What Is It and How Does It Work? (Mechanism of Action)

Omidria is a bispecific pharmaceutical agent that combines an alpha-1 adrenergic receptor agonist (Phenylephrine) with a potent nonsteroidal anti-inflammatory drug (Ketorolac). Its mechanism of action is designed to address two distinct physiological challenges that occur when the eye is surgically opened.

At the molecular and physiological level, the mechanism works as follows:

1. Mydriasis Maintenance (Phenylephrine): Phenylephrine acts as a potent agonist at the alpha-1 adrenergic receptors located on the radial dilator muscle of the iris. During surgery, surgical trauma often triggers a “miotic” response, where the pupil constricts in reaction to touch or fluid flow. By stimulating these receptors throughout the procedure, Omidria ensures the dilator muscle remains contracted, maintaining a wide surgical field.
2. Inflammation Inhibition (Ketorolac): Ketorolac is a non-selective inhibitor of the cyclooxygenase (COX-1 and COX-2) enzymes. When the eye is manipulated during surgery, the body naturally releases prostaglandins—lipids that trigger inflammation, cause the pupil to constrict (miosis), and signal pain to the brain. Ketorolac inhibits the synthesis of these prostaglandins at the source. By blocking COX enzymes within the anterior chamber, Omidria prevents the miosis that usually follows prostaglandin release and significantly reduces the inflammatory markers that lead to post-operative swelling and discomfort.

By delivering these two agents continuously through the surgical irrigation fluid, Omidria provides a steady-state concentration of medication directly to the iris and ciliary body, ensuring a more predictable surgical outcome than traditional “loading” with preoperative drops alone.

FDA-Approved Clinical Indications

Omidria is indicated for use in adult and pediatric patients undergoing intraocular procedures that involve the lens.

• Primary Indication: Maintaining pupil size by preventing intraoperative miosis (pupil constriction) and reducing postoperative ocular pain during cataract surgery or intraocular lens (IOL) replacement.
• Other Approved & Off-Label Uses: While primarily used in cataract surgery, some surgeons utilize it in other anterior segment procedures where pupil stability is a priority, though these are considered extensions of its primary ophthalmic surgical category.

Primary Ophthalmology Indications for Omidria:

• Preserving Visual Acuity: By preventing miosis, the drug reduces the risk of surgical complications such as posterior capsule rupture or iris trauma. Avoiding these complications is essential for ensuring the patient achieves their maximum Best Corrected Visual Acuity (BCVA) post-operatively.
• Stabilizing the Ocular Environment: The inhibition of prostaglandins helps maintain the blood-aqueous barrier, reducing the incidence of post-operative inflammation.
• Managing Intraoperative Safety: A stable, large pupil provides the surgeon with a clear view of the lens capsule, which is critical in patients with “Intraoperative Floppy Iris Syndrome” (IFIS).

Dosage and Administration Protocols

Omidria is administered via a specialized clinical protocol. It is not a drug that a patient applies themselves. Instead, it is integrated into the surgical system.

Indication	Standard Dose	Frequency
Cataract Surgery / IOL Replacement	4 mL Omidria per 500 mL Irrigation Solution	Continuous irrigation during the surgical procedure

Administration Specifics:

• Dilution: One single-use vial (4 mL) of Omidria is added to a 500 mL bottle of balanced salt solution (BSS) or other internal irrigation fluid.
• Delivery: The diluted solution is used for continuous irrigation of the anterior chamber during the phacoemulsification and lens implantation stages of the surgery.
• Storage: The solution must be used within 24 hours of preparation if stored at room temperature.
• Technique: Unlike topical drops, there is no need for “punctal occlusion” as the drug is cleared from the eye at the end of the surgical procedure.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Current clinical study data (2020-2026) reinforces Omidria as a standard-of-care adjunct in modern cataract surgery. In pivotal Phase 3 clinical trials, Omidria demonstrated a statistically significant advantage in maintaining pupil diameter. Specifically, patients treated with Omidria showed a mean pupil diameter change of only 0.1 mm during the procedure, compared to a constriction of 1.5 mm or more in the placebo group.

The reduction in pain is equally measurable. Numerical data indicates that significantly more patients in the Omidria group reported a “pain-free” experience (0 on a 10-point scale) during the first 10 to 12 hours after surgery. Regarding safety and vision preservation, research data shows a lower incidence of Cystoid Macular Edema (CME) in patients receiving intraocular NSAIDs like Ketorolac. By maintaining a stable Central Retinal Thickness (CRT) measured via OCT post-operatively, Omidria is efficacious in preventing the inflammatory vision loss that can sometimes follow even successful surgeries. Furthermore, surgeons have reported a 7% to 10% reduction in total surgical time when using the medication due to the improved visibility and stability of the pupil.

Safety Profile and Side Effects

There is no Black Box Warning for Omidria. It is generally well-tolerated when used as part of the surgical irrigation protocol.

Common Side Effects (>10%):

• Increased intraocular pressure (temporary post-surgical spike).
• Eye irritation or foreign body sensation (common to the surgery itself).
• Posterior capsule opacification (a long-term surgical consideration, not directly caused by the drug).

Serious Adverse Events:

• Systemic Absorption: While rare due to localized use, phenylephrine can theoretically cause transient increases in blood pressure or heart rate (bradycardia/hypotension risks are minimal compared to topical application).
• Endophthalmitis: As with any intraocular entry, there is a risk of infection, though Omidria is a Preservative-Free single-use vial designed to minimize this risk.
• Corneal Melting: While NSAIDs are sometimes associated with corneal thinning, this is typically linked to chronic topical use rather than a one-time intraocular irrigation.

Management Strategies: Surgeons utilize sterile administration techniques to ensure the Omidria-BSS mixture remains uncontaminated. Post-operative care involves monitoring for “floaters” or sudden pain, which could indicate inflammation or pressure spikes.

Research Areas

Direct Clinical Connections:

Recent research is investigating Omidria’s interaction with the Retinal Pigment Epithelium (RPE) and its potential neuroprotective effects. By limiting the global inflammatory response within the eye during surgery, researchers believe it may help protect the health of the optic nerve, especially in patients with pre-existing glaucoma.

Generalization:

Active clinical trials (2020-2026) are focusing on Novel Delivery Systems, such as pre-mixed irrigation bags to reduce the risk of pharmacy errors. There is also ongoing research into the use of Omidria as a Targeted Therapy in complex surgeries, such as those involving Corneal Transplants or vitrectomies, where inflammatory control is paramount.

Severe Disease & Surgical Integration:

In patients with advanced eye disease, Omidria is researched for its efficacy in preventing blindness by facilitating safer surgery in high-risk eyes. For example, in end-stage glaucoma patients where any intraoperative pressure fluctuation is dangerous, the stability provided by Omidria is considered a critical adjunct to surgical success.

Disclaimer: These studies regarding Omidria’s extended applications and novel delivery systems are currently in the preclinical or early clinical phase and are not yet applicable to practical or professional clinical scenarios. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Surgeons perform Baseline Visual Acuity, Tonometry (IOP measurement), and a Slit-lamp exam to assess iris health and pupil dilating potential.
• Ocular Imaging: Optical Coherence Tomography (OCT) is performed to ensure the retina is healthy prior to surgery.
• Specialized Testing: Corneal Topography and biometry are used to plan the lens power.
• Screening: Patients are screened for a history of ocular surgeries, allergies to NSAIDs (like aspirin), or history of Herpes Simplex Keratitis.

Monitoring and Precautions

• Vigilance: Monitoring for a “rebound” in pressure (IOP) during the first 24 hours post-surgery.
• Lifestyle: Advise patients on UV protection (sunglasses), as the eye will be dilated and sensitive to light immediately after the procedure. Eyelid hygiene (lid scrubs) is encouraged to prevent infection.
• Nutrition: Patients are encouraged to continue their AREDS2 formula or other dietary supplements as part of their general ocular health.

Do’s and Don’ts

• DO tell your surgeon if you have ever taken prostate medications (like Flomax), as these increase the risk of floppy iris syndrome.
• DO follow all post-operative drop instructions carefully to support the work started by Omidria.
• DON’T rub your eye after surgery; the stability of the IOL and the healing of the incision are paramount.
• DON’T miss your one-day post-operative appointment where your doctor will check your eye pressure.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice or a recommendation for a specific surgical outcome. The information provided is not a substitute for professional medical judgment. Standard clinical protocols and FDA approvals are subject to change. Omidria is a prescription-only surgical adjunct, and its use is at the sole discretion of the operating ophthalmic surgeon. Patients should discuss the risks and benefits of all surgical medications with their healthcare provider. All medical information is provided for the purpose of fostering patient education and academic understanding.